- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04445337
Stellate Ganglion Blockade in COVID-19 Positive Patients
May 17, 2022 updated by: Michael Lankhorst, University of Nebraska
This study will establish the safety and efficacy of using stellate ganglion blocks in patients with ARDS due to COVID-19 disease.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The attending proceduralist will perform the SGB in the ICU.
Nurse will provide patient monitoring and assistance during the procedure.
Standard monitors and ACLS resuscitative equipment will be immediately available.
A norepinephrine solution will be at bedside to treat potential hypotension associated with SGB.
The SGB perineural catheter will be placed using standard sterile technique.
Initial perineural bolus injection - clonidine 100 mcg, Decadron PF 5mg, and 0.25% bupivacaine 5 ml is delivered.
An OnQ perineural infusion 0.2% bupivacaine will be initiated at 2ml/hr for 5 days.
Acute pain service will discontinue infusion and remove the catheter after 5 days.
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Any patient between the ages of 19-85 with laboratory established COVID-19 infection (via rRT-PCR) requiring critical care in an intensive care unit.
- Signs or symptoms consistent with ARDS must be present.
- The syndrome must present acutely, PaO2/FIO2 ≤ 200 mm Hg, bilateral infiltrates on chest radiograph or CT not due to cardiac failure, need for non-invasive or invasive mechanical ventilation, and any cardiac dysrhythmia (excluding sinus tachycardia).
Exclusion Criteria:
- Hemodynamic instability (>2 vasopressors)
- pre-hospital diagnosis of heart failure or fluid overload
- anatomical inability to perform block
- prior sympathectomy
- patient currently enrolled in another clinical trial for COVID-19 or respiratory distress/ARDS
- uncorrectable coagulopathy, already on ECMO, already on Nitric Oxide, pre-existing multi-organ failure (>2 organ systems).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Open Label SGB
Initial perineural bolus injection - clonidine 100 mcg, Decadron PF 5mg, and 0.25% bupivacaine 5 ml will be used for SGB block.
|
An injection of local anesthetic into the front of the neck.
Medication used for the block include- clonidine 100 mcg, Decadron PF 5mg, and 0.25% bupivacaine 5 ml is delivered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the safety of a new modified stellate ganglia block (SGB) in ARDS
Time Frame: 3 month
|
Adverse events related to SGB.
|
3 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the efficacy of a new modified stellate ganglia block (SGB) in ARDS
Time Frame: 3 month
|
All adverse events.
|
3 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 15, 2020
Primary Completion (Actual)
October 1, 2021
Study Completion (Actual)
November 1, 2021
Study Registration Dates
First Submitted
June 9, 2020
First Submitted That Met QC Criteria
June 22, 2020
First Posted (Actual)
June 24, 2020
Study Record Updates
Last Update Posted (Actual)
May 24, 2022
Last Update Submitted That Met QC Criteria
May 17, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 603.20.FB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID 19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on Stellate Ganglion Block
-
University of PennsylvaniaRecruitingVentricular TachycardiaUnited States
-
West Virginia UniversityCompletedCOVID-19 | Acute Respiratory Distress SyndromeUnited States
-
IRCCS Policlinico S. MatteoRecruiting
-
Institute for Clinical and Experimental MedicineRecruitingVentricular Fibrillation | Ventricular Tachycardia | Ventricular Arrythmia | Block | Arrhythmic StormCzechia
-
Tanta UniversityMohamad Gamal Elmawy, M.DRecruiting
-
Eslam Ayman Mohamed ShawkiUnknownStellate Ganglion Block | Radial Artery CannulationEgypt
-
Aswan UniversityRecruitingHemodialysis | Arteriovenous Fistula | Stellate Ganglion Block | Major Lower Limb Orthopedic SurgeryEgypt
-
Beijing Tiantan HospitalRecruitingAneurysmal Subarachnoid Hemorrhage | Stellate Ganglion Block | Cerebral VasospasmChina
-
VA Office of Research and DevelopmentAnalydata, IncRecruiting
-
Beijing Tiantan HospitalNot yet recruitingSubarachnoid Hemorrhage, Aneurysmal | Cerebral Vasospasm